Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2007 2
2008 3
2009 3
2010 4
2011 2
2012 3
2013 5
2014 2
2015 2
2016 9
2017 5
2018 5
2019 8
2020 8
2021 6
2022 7
2023 12
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression.
Ye J, Baer JM, Faget DV, Morikis VA, Ren Q, Melam A, Delgado AP, Luo X, Mullick Bagchi S, Belle JI, Campos E, Friedman M, Veis DJ, Knudsen ES, Witkiewicz AK, Powers S, Longmore GD, DeNardo DG, Stewart SA. Ye J, et al. Among authors: denardo dg. Cancer Discov. 2024 Apr 17:OF1-OF22. doi: 10.1158/2159-8290.CD-23-0426. Online ahead of print. Cancer Discov. 2024. PMID: 38683543
Senescent CAFs mediate immunosuppression and drive breast cancer progression.
Ye J, Baer JM, Faget DV, Morikis VA, Ren Q, Melam A, Delgado AP, Luo X, Mullick Bagchi S, Belle JI, Campos E, Friedman M, Veis DJ, Knudsen ES, Witkiewicz AK, Powers S, Longmore GD, DeNardo DG, Stewart SA. Ye J, et al. Among authors: denardo dg. Cancer Discov. 2024 Apr 29. doi: 10.1158/2159-8290.CD-23-0426. Online ahead of print. Cancer Discov. 2024. PMID: 38683161
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K, Somani V, Khawar IA, Chen HP, Dodhiawala PB, Li L, Geng Y, Mo CK, Mahsl J, Ding L, Govindan R, Davies S, Mudd J, Hawkins WG, Fields RC, DeNardo DG, Knoerzer D, Held JM, Grierson PM, Wang-Gillam A, Ruzinova MB, Lim KH. Bulle A, et al. Among authors: denardo dg. Nat Commun. 2024 Mar 20;15(1):2503. doi: 10.1038/s41467-024-46811-w. Nat Commun. 2024. PMID: 38509064 Free PMC article.
Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma.
Pothuri VS, Hogg GD, Conant L, Borcherding N, James CA, Mudd J, Williams G, Seo YD, Hawkins WG, Pillarisetty VG, DeNardo DG, Fields RC. Pothuri VS, et al. Among authors: denardo dg. Oncoimmunology. 2024 Mar 15;13(1):2320411. doi: 10.1080/2162402X.2024.2320411. eCollection 2024. Oncoimmunology. 2024. PMID: 38504847 Free PMC article.
Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma.
Zhang X, Detering L, Heo GS, Sultan D, Luehmann H, Li L, Somani V, Lesser J, Tao J, Kang LI, Li A, Lahad D, Rho S, Ruzinova MB, DeNardo DG, Dehdashti F, Lim KH, Liu Y. Zhang X, et al. Among authors: denardo dg. ACS Pharmacol Transl Sci. 2023 Dec 5;7(1):285-293. doi: 10.1021/acsptsci.3c00303. eCollection 2024 Jan 12. ACS Pharmacol Transl Sci. 2023. PMID: 38230294
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Wang-Gillam A, et al. Among authors: denardo dg. Clin Cancer Res. 2023 Nov 14;29(22):4698. doi: 10.1158/1078-0432.CCR-23-2993. Clin Cancer Res. 2023. PMID: 37960920 No abstract available.
91 results